You are here

J Med Genet DOI:10.1136/jmedgenet-2014-102478

Meta-analysis identifies loci affecting levels of the potential osteoarthritis biomarkers sCOMP and uCTX-II with genome wide significance.

Publication TypeJournal Article
Year of Publication2014
AuthorsRamos, YFM, Metrustry, S, Arden, N, Bay-Jensen, AC, Beekman, M, de Craen, AJM, L Cupples, A, Esko, T, Evangelou, E, Felson, DT, Hart, DJ, Ioannidis, JPA, Karsdal, M, Kloppenburg, M, Lafeber, F, Metspalu, A, Panoutsopoulou, K, P Slagboom, E, Spector, TD, van Spil, EWE, Uitterlinden, AG, Zhu, Y, Valdes, AM, van Meurs, JBJ, Meulenbelt, I
Corporate AuthorsarcOGEN Consortium, TreatOA Collaborators
JournalJ Med Genet
Volume51
Issue9
Pages596-604
Date Published2014 Sep
ISSN1468-6244
KeywordsBiomarkers, Cartilage Oligomeric Matrix Protein, Collagen Type II, Genetic Variation, Genome-Wide Association Study, Genotype, Humans, Membrane Proteins, Osteoarthritis, Peptide Fragments, Polymorphism, Single Nucleotide, Receptors, Immunologic
Abstract

BACKGROUND: Research for the use of biomarkers in osteoarthritis (OA) is promising, however, adequate discrimination between patients and controls may be hampered due to innate differences. We set out to identify loci influencing levels of serum cartilage oligomeric protein (sCOMP) and urinary C-telopeptide of type II collagen (uCTX-II).

METHODS: Meta-analysis of genome-wide association studies was applied to standardised residuals of sCOMP (N=3316) and uCTX-II (N=4654) levels available in 6 and 7 studies, respectively, from TreatOA. Effects were estimated using a fixed-effects model. Six promising signals were followed up by de novo genotyping in the Cohort Hip and Cohort Knee study (N = 964). Subsequently, their role in OA susceptibility was investigated in large-scale genome-wide association studies meta-analyses for OA. Differential expression of annotated genes was assessed in cartilage.

RESULTS: Genome-wide significant association with sCOMP levels was found for a SNP within MRC1 (rs691461, p = 1.7 × 10(-12)) and a SNP within CSMD1 associated with variation in uCTX-II levels with borderline genome-wide significance (rs1983474, p = 8.5 × 10(-8)). Indication for association with sCOMP levels was also found for a locus close to the COMP gene itself (rs10038, p = 7.1 × 10(-6)). The latter SNP was subsequently found to be associated with hip OA whereas COMP expression appeared responsive to the OA pathophysiology in cartilage.

CONCLUSIONS: We have identified genetic loci affecting either uCTX-II or sCOMP levels. The genome wide significant association of MRC1 with sCOMP levels was found likely to act independent of OA subtypes. Increased sensitivity of biomarkers with OA may be accomplished by taking genetic variation into account.

URLhttp://jmg.bmj.com/cgi/pmidlookup?view=long&pmid=25057126
DOI10.1136/jmedgenet-2014-102478
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/25057126?dopt=Abstract

Alternate JournalJ. Med. Genet.
PubMed ID25057126
Grant ListN01 HC025195 / HC / NHLBI NIH HHS / United States
091746/Z/10/Z / / Wellcome Trust / United Kingdom
18030 / / Arthritis Research UK / United Kingdom
ref. 079771 / / Wellcome Trust / United Kingdom